Edition:
India

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

34.47USD
18 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$34.47
Open
$34.43
Day's High
$34.53
Day's Low
$34.24
Volume
705,884
Avg. Vol
1,057,975
52-wk High
$35.90
52-wk Low
$28.74

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.48
Market Cap(Mil.): $234,655.20
Shares Outstanding(Mil.): 6,900.50
Dividend: 1.07
Yield (%): 3.14

Financials

  RHHBY.PK Industry Sector
P/E (TTM): 22.17 30.18 34.10
EPS (TTM): 1.54 -- --
ROI: 20.69 12.97 12.64
ROE: 38.71 14.15 17.18

Pfizer's Avastin biosimilar wins FDA approval

Pfizer Inc said on Friday that the U.S. Food and Drug Administration had approved its biosimilar to Roche Holding AG's blockbuster cancer treatment Avastin.

28 Jun 2019

Pfizer's Avastin biosimilar wins FDA approval

June 28 Pfizer Inc said on Friday that the U.S. Food and Drug Administration had approved its biosimilar to Roche Holding AG's blockbuster cancer treatment Avastin.

28 Jun 2019

Roche's combo lymphoma treatment wins U.S. FDA approval

(This June 10 story deletes paragraph 9 to clarify that retreatment with Polivy has not been studied.)

15 Jun 2019

CORRECTED-UPDATE 3-Roche's combo lymphoma treatment wins U.S. FDA approval

June 10 The U.S. Food and Drug Administration on Monday granted earlier-than-expected approval to Roche Holding AG's antibody- Polivy for treatment of patients with advanced lymphoma.

15 Jun 2019

Roche's combo lymphoma treatment wins FDA's accelerated approval

June 10 The U.S. Food and Drug Administration granted accelerated approval to Roche Holding AG's combo lymphoma treatment for previously treated patients, the company said on Monday

10 Jun 2019

Roche sees no Brexit interruption for patients

ZURICH, April 17 Roche holding ag ceo says sales growth for hemlibra primarily driven by non-inhibitors patients Roche holding ag ceo says spark therapeutics acquisition planned to be completed in first half Roche holding ag ceo says still believes biosimilars will enter market in u.s. In second half Roche holding ag says sees continued "very strong" growth for ocrevus after entry of novartis's mayzent Roche holding ag drugs chief says gantenerumab for alzheimers remains a high risk

17 Apr 2019

Roche says $4.3 billion Spark offer still on track for June completion

ZURICH Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.

03 Apr 2019

Roche says $4.3 billion Spark offer still on track for June completion

ZURICH Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.

03 Apr 2019

UPDATE 1-Roche extends Spark offer after getting only 29 pct

ZURICH, April 3 Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting only 29.4 percent of Spark's shares in a tender originally due to end on Wednesday.

03 Apr 2019

Roche extends Spark offer after getting 29 pct in tender

ZURICH, April 3 Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting 29.4 percent of Spark's shares in a tender originally due to end on Wednesday.

03 Apr 2019

Earnings vs. Estimates